News | April 30, 2021
Lonza and Moderna enter new agreement to double drug substance production for COVID-19 vaccine
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19
This achievement enables the company to strengthen its presence in the high growth market of South Asian countries
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
_256_384.jpeg)
Against the present demand from 20 states of 6,785 MT/day of Liquid Medical Oxygen, the Government of India has from 21st April allocated 6,822 MT/day to these states
These media reports are based on incorrect facts and are without any basis.
The country has constantly worked with the spirit of public-private partnership
Essential medicines were made available to more than 150 countries around the world during the pandemic
The company also plans to register the similar range of products in the neighbouring countries.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)